Gilead Scraps HR-MDS Trial; FDA OKs Verrica's Molluscum Treatment
- July 22nd, 2023
- 269 views
Gilead Sciences, Inc. (Nasdaq: GILD) announced the termination of the Phase 3 ENHANCE study evaluating magrolimab plus azacitidine as a first-line treatment for higher-risk myelodysplastic syndromes (HR-MDS) due to futility based on a planned analysis.
The safety data observed in this study aligns with the established magrolimab profile and the usual adverse events found in this patient population, prompting Gilead's recommendation to discontinue magrolimab treatment for MDS patients.
On Friday, $GILD closed at $80.64, reflecting a gain of $0.70 (+0.88%)
In other news, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) gained U.S. FDA approval for YCANTH (cantharidin) topical solution to treat molluscum contagiosum (molluscum) in adult and pediatric patients aged 2 years and older.
Molluscum is a highly contagious viral skin infection, mainly affecting children. YCANTH, a drug-device combination product, is expected to be available through healthcare professionals by September 2023.
$VRCA closed at $7.45 on Friday, up $0.28 (+3.83%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login